Close menu




September 8th, 2021 | 12:28 CEST

PuriflOH, Bayer, Philips - Innovations as yield drivers

  • Investments
Photo credits: pixabay.com

Innovations enrich our everyday lives in many ways. The following companies have developed innovative solutions for health and climate in the broadest sense that help remedy important problems. The focus here is on water, a scarce resource, and air purification, which in times of Corona plays an increasingly important role. Which Company has the best opportunities?

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: PURIFLOH LTD | AU0000010548 , BAYER AG NA O.N. | DE000BAY0017 , KONINKL. PHILIPS EO -_20 | NL0000009538

Table of contents:


    PURIFLOH LIMITED - Innovator from Australia with worldwide patents

    Founded in Australia with a US office in Detroit, PuriflOH has developed innovative and globally patented technology for cleaning air, water and surfaces in residential, commercial and industrial settings. According to the Company, PuriflOH has developed the first and only single solution to remove biological and chemical contaminants from the air through a two-step process.

    IP licensing and partnership opportunities with air purification equipment manufacturers for residential, commercial and industrial applications are currently being explored. PuriflOH solutions are easily expandable and, therefore, scalable. In the past, the Company undertook significant research activities to develop the Free Radical Generator (FRG) technology. Now, the Company is leveraging the expertise of Somnio Group for further development.

    Most recently, the Australians announced that commercialization activities would resume in Australia with two new products. These are the Air Conditioning Environmental Remediation Treatment (ACERT) and the Whole of Room Air Purifier (WRAP). In addition, PuriflOH built relationships with Aspen Medical, a healthcare solutions company, and Osmoflo, a water treatment company. Both partners play an important role in the future commercialization of the products.

    The Company is still in the red, but this is characteristic of the relatively early stage. However, the loss was significantly reduced in the fiscal year. In addition, the Company secured an AUD 1 million financing facility from its major shareholder Dilato. Currently, PuriflOH is valued at AUD 53 million. As the products are commercialized, operating income will quickly materialize. Technology-savvy investors should put the shares on their watchlist.

    BAYER AG - Turnaround in sight?

    Climate change is again causing problems for agriculture this year. According to the recently published harvest report by the German Federal Ministry of Agriculture and statements by the farmers' association, heavy rain and hail will lead to a 2.7% decline in the grain harvest this year. Compared to the years 2015 to 2020, this is even a decrease of 4.8%. While too much water has caused problems in this country, water scarcity is a major problem globally. 70% of the world's water is consumed by agriculture. By the end of the decade, demand will already exceed supply. Water is thus becoming a crucial bottleneck factor.

    Even if Bayer is more present in the media through its pharmaceuticals business and its cooperation with the Corona vaccine manufacturer CureVac, whose vaccine has not yet reached the marketing stage due to a lack of vaccine protection, Bayer's strong second pillar is agricultural chemistry. Here, the DAX-listed Company is focusing on targeted research activities to enable water-efficient agriculture. It also develops and markets products and technologies for improved wastewater treatment. Disappointing half-year figures and the lawsuits pending for some time in the USA in connection with carcinogenic fertilizers from the acquired competitor Monsanto led to a significant underperformance of around 10% against the DAX this year. 2021 will undoubtedly be a challenging year for the Group, but analysts expect things to pick up again significantly in 2022. The 2022 P/E ratio is 10, and the stock is currently interesting for anti-cyclical investors.

    KONINKLIJKE PHILIPS NV - Established player with industry-standard valuation

    Koninklijke Philips NV is a leading healthcare technology company with a wide range of products from healthy living and prevention to diagnosis, treatment and home care. The Group uses advanced technologies and sound clinical and consumer insights to provide integrated solutions. The Dutch-based Company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, and consumer health and home care. In Corona times, the air purifier sector has taken on greater importance. The Group is currently valued at around EUR 37 billion, 2 times projected 2022 sales and a 2022 P/E of 24.


    The featured stocks focus on climate, health and water as a resource. In doing so, all companies focus on different areas. Bayer is one of the leading players in agricultural chemicals. After a year of losses, next year should see a return to gratifying profits - this makes the shares interesting. Anyone who wants to invest in a young technology company that offers a range of innovative solutions should take a closer look at the PuriflOH share.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Fabian Lorenz on June 29th, 2022 | 12:18 CEST

    Buy or sell? Nel, Zalando, Aspermont under analyst review

    • Commodities
    • Investments
    • Hydrogen
    • Mining

    After the heavy losses of the past months, a countermovement seems to be starting at the moment. Whether this will turn into a real summer rally remains to be seen. Buy or sell is the question. Analysts see a price potential of over 50% for Nel ASA. Even though competition from China and India is increasing. Aspermont also appears attractive at the current price level. The latest quarterly figures were positive, and the positioning of the small-cap in the booming commodities sector is promising. At Zalando, analysts react to the profit warning, and the price targets are significantly reduced. Nevertheless, some advise buying the online fashion retailer, but not everyone.

    Read

    Commented by André Will-Laudien on June 24th, 2022 | 11:19 CEST

    TUI, Pathfinder Ventures, Lufthansa - The travel market is back - where are the share prices?

    • travel
    • Investments
    • Camping

    The travel market has changed dramatically since 2019 in light of the Corona pandemic. Due to the most extensive pandemic standstill in 2020, the capacities for flights, rail traffic and accommodation were adjusted downwards dramatically. Major cost reductions occurred primarily through de-occupancy and staff reductions. Travel companies cut their basic capacity utilization with partners to such an extent that many smaller operations had to pull out of the race, and large corporations could only survive with extensive state aid. Now, however, the situation has turned 180 degrees and demand for travel is exploding. However, this time it seems difficult to ramp up the reduced capacities in line with demand. We look at the opportunities of three typical industry players.

    Read

    Commented by Armin Schulz on June 24th, 2022 | 10:15 CEST

    Commerzbank, Triumph Gold, Bitcoin Group - Inflation alert! Which stocks bring returns in this market environment?

    • Gold
    • Crypto
    • Investments

    We have not seen such high inflation for decades. Looking back, it becomes clear that one cannot compare the situation back then with today. Back then, interest rates were at 12%, and as a saver, you could generate an increase in value for your money despite inflation. Today, interest rates are much lower than inflation. Putting money in a savings account will not bring any investor a profit. If you want to protect your money, the first thing that comes to mind is gold because it is considered crisis-proof. But nowadays, it almost seems as if cryptocurrencies could outperform gold. Alternatively, one can bet on stocks that cover these areas. We take a closer look at three companies.

    Read